Evidence from randomized controlled trials, meta-analyses, and subgroup analyses

JAMA

Volumn 303, Issue 13, 2010, Pages 1253-

  Vosk, Arno ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DATA ANALYSIS; EVIDENCE BASED MEDICINE; GOVERNMENT; HEALTH CARE COST; HEALTH CARE FINANCING; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; CONFLICT OF INTEREST; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; NOTE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STANDARD; META ANALYSIS; METHODOLOGY; PATIENT CARE;

CONFLICT OF INTEREST; EVIDENCE-BASED MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; SAMPLE SIZE; HUMANS; META-ANALYSIS AS TOPIC; PATIENT-CENTERED CARE; RESEARCH DESIGN;

EID: 77950483899     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.364     Document Type: Letter

References (4)

1. Hennekens CH, DeMets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA. 2009;302(21):2361-2362.
2. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-1170.
3. Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry. 2007; 191: 82-83.
4. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454-465.